
How Businesses Can Stay Steady Amid EPA Uncertainty
getty
We're operating in one of the most uncertain regulatory environments in decades. As federal environmental policy undergoes rapid and often unpredictable shifts through reversals, reinterpretations and sometimes outright dismantling, businesses are left navigating a compliance landscape that feels more like quicksand than solid ground.
From water discharge regulations and air quality thresholds to chemical usage guidelines, the rules are changing fast. In my role, I've seen firsthand how this uncertainty is creating real pressure for environmental, health and safety (EHS) professionals. For many companies, staying compliant feels like trying to hit a moving target blindfolded.
Let's call it what it is: Environmental compliance is no longer anchored in consistency. Federal definitions and enforcement mechanisms like those outlined in the Clean Air Act, Clean Water Act and the ever-controversial 'Waters of the United States' (WOTUS) are in flux. The result? Critical permitting decisions are left in limbo. Projects stall, timelines slip and operational momentum suffers.
Businesses that operate across state lines face another layer of complexity. Each state is responding differently to changes at the federal level. California, for example, remains vigilant and aggressive in its EHS enforcement, while other states take a more hands-off approach. The practical reality for companies is that compliance doesn't come with a one-size-fits-all manual.
On top of all this is uncertainty in our judicial system. Court decisions like Sackett v. EPA have redefined the scope of federal environmental authority. When judges become the arbiters of what constitutes a wetland or navigable water, businesses are left guessing how long a permit will hold, or if it's needed at all.
Then there's the political pendulum. Every change in administration seems to rewrite the definition of what compliance looks like. Take PFAS regulations or the March 2025 EPA statement as examples: what one administration tightens, the next might loosen. The whiplash is real.
All of this legal and regulatory volatility has very tangible consequences. Project development is delayed or halted because permits are stuck in procedural purgatory. Compliance teams burn out trying to keep pace with the changes. And when missteps occur, because they inevitably do, companies face financial penalties, public scrutiny and reputational risk.
There's a cost to being reactive. Get ahead of the chaos. Build for change rather than stability.
The best companies don't chase regulations; they anticipate them. They invest in compliance systems designed to flex and adapt as laws evolve. This includes digital platforms for real-time monitoring, data analytics tools to track impact and dashboards that make it easy to report progress internally and externally.
But systems alone aren't enough. You also have to invest in people. The people are the core of the business. EHS teams need the training, support and leadership to interpret rules and operate confidently amid ambiguity. You want to create a resilient team of professionals who don't just react but lead.
Many leaders choose to offload mental strain from their internal team by bringing in experienced partners who can track regulatory changes full-time. If you go this route, it's important to find the right partner whose job is to know the regulations and how they'll evolve, so you don't have to spend all your energy there.
With so much uncertainty, it's tempting to deprioritize sustainability until the dust settles. But sustainability isn't just about compliance. It's about preserving your company values, longevity and reputation. Sustainability is about the air our employees breathe, the water our communities drink and the kind of company we want to be known as.
Businesses that stay committed to environmental stewardship even when regulations are unclear are playing the long game. They're minimizing risk, protecting their workforce, and building public trust.
Sustainability also supports safety, another key pillar of successful operations. If you're aligning your environmental, safety and compliance goals, you're protecting your people and your brand.
If there's one takeaway I'd emphasize, it's this: Companies do have the ability to find stability in an unstable regulatory environment. You can't control the courts or the political climate, but you can control how prepared your team is. You can control the systems you invest in, the partners you rely on and the culture you build internally.
Transparency is key internally with teams and externally with stakeholders. Clear reporting, routine audits and shared dashboards create alignment and trust. Make sure your team is equipped with the best possible technology and is mentally and physically well. That's what drives compliance, not just policy memoranda.
We're in an era where regulation will likely continue to be turbulent. But if your business prioritizes proactive systems, supports your people and partners wisely, you can operate with confidence—even when the rules keep changing.
In the end, compliance is a mindset. And in today's environment, that mindset is more important than ever.
Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi
We recently published . Hudbay Minerals Inc. (NYSE:HBM) is one of the best-performing stocks on Wednesday. Hudbay Minerals grew its share prices for a second day on Wednesday, up 15.03 percent to close at $11.33 apiece, following an impressive earnings performance and a $600-million investment from Mitsubishi Corp. In its updated report, Hudbay Minerals Inc. (NYSE:HBM) said it swung to a net income attributable to shareholders of $117.7 million from an attributable net loss of $16.5 million in the same period last year, driven by higher gross margins and strong cost control. Revenues increased by 26 percent to $536.4 million from $425.5 million year-on-year. 'With the strong performance in the first half of the year, we are reaffirming our full year consolidated production guidance and are favourably tracking well below our full year consolidated cost guidance for 2025,' said Hudbay Minerals Inc. (NYSE:HBM) President and CEO Peter Kukielski. For the full-year period, the company is targeting to produce between 117,000 and 149,000 tons of copper, as well as 247,500 to 308,000 ounces of gold. In other news, Hudbay Minerals Inc. (NYSE:HBM) was able to raise $600 million in fresh funds from Mitsubishi Corp. after the latter acquired a 30-percent stake in Copper World LLC. Under the agreement, Mitsubishi will pay an upfront cash of $420 million, with the balance to serve as a matching contribution within an 18-month period. While we acknowledge the potential of HBM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data